Alembic Pharmaceuticals reported a steady operating performance in the third quarter, supported by consistent execution across its India and international businesses. Revenue rose 10.8% year-on-year to ₹1,876.3 crore, while EBITDA increased 12.8% to ₹293.5 crore.
EBITDA margin improved slightly to 15.6%, compared to 15.4% in the same quarter last year, reflecting stable operating efficiency.
However, net profit declined due to a one-time impact linked to employee benefits.
While the topline and operating profit improved, the bottom line was affected by a one-off provision.
| Particulars | Q3 | YoY Change |
| Revenue | ₹1,876.3 crore | +10.8% |
| EBITDA | ₹293.5 crore | +12.8% |
| EBITDA Margin | 15.6% | Up from 15.4% |
| Net Profit | ₹132 crore | -4.1% |
Net profit fell 4.1% year-on-year to ₹132 crore. The decline was mainly due to a one-time provision of ₹42 crore towards employee benefits, following changes under the new labour code.
Excluding this one-off cost, profit performance would have been stronger and more in line with the growth in operating earnings.
The India branded business posted 6% growth to ₹652 crore. Growth was led by:
The anti-infective portfolio grew broadly in line with market trends. The company also introduced four new products during the quarter, which supported its domestic momentum.
Alembic’s international performance remained stable, with both the US and other global markets contributing.
| Segment | Revenue | YoY Change |
| US Generics | ₹553 crore | +6% |
| Ex-US International Generics | ₹406 crore | +36% |
The US business also saw two new product launches during the quarter. Alembic received seven ANDA approvals, taking its cumulative approvals to 232, strengthening its pipeline for future launches.
The API business grew 2% year-on-year to ₹264 crore.
The company continued to focus on research and development, investing around 9% of revenue into R&D. It also made progress in integrating Utility Therapeutics. The launch of Pivya™ is expected in Q4, which could support the company’s US branded portfolio.
Following the earnings announcement, Alembic Pharmaceuticals share price was trading 1.79% higher at ₹812.65 on the NSE, indicating that markets largely viewed the results positively despite the profit decline.
Read more: 360 ONE Mutual Fund to Launch Its First SIF on February 6, 2026.
Alembic Pharmaceuticals delivered a steady Q3 performance, with healthy revenue growth and a slight improvement in margins. While net profit dipped, the fall was driven mainly by a one-time labour code-related provision. With strong growth in ex-US markets, continued ANDA approvals, and sustained R&D investment, the company appears well-positioned for stable progress in the coming quarters.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Feb 5, 2026, 2:42 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN